Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended temozolomide versus observation after six cycles in newly diagnosed glioblastoma
ACTRN12618001944224Phase 3Completed
- Sponsor
- WEHI
- Start
- Mar 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) and brain cancer comparing Observation with standard follow-up with Additional six cycles of temozolomide (2 arms). Primary endpoint: Overall survival. Started Mar 2019; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)brain cancer
Beyond the preview
Go deeper on ACTRN12618001944224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001944224.